Therapy candidate LYT-100 worked better than Esbriet, with fewer side effects, to slow lung function decline in IPF patients, ...
PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...
PureTech Health's Phase 2b trial of deupirfenidone for IPF met its primary endpoint, showing significant lung function ...
GlobalData on MSN5d
PureTech sees success in Phase IIb Pulmonary Fibrosis trialResearch carried out by the company found that daily doses of deupirfenidone could slow the degeneration of the lungs in ...
PureTech Health plc (PRTC, PRTC.L) announced positive results from the ELEVATE IPF trial. This Phase 2b, randomized, double-blind, ...
Russian scientists have defeated the main consequence of coronavirus infection — exercise intolerance. This is reported by ...
Puretech Health plc has announced phase IIb data showing its reformulation of pirfenidone has improved the tolerability and increased the efficacy of the marketed antifibrotic in the treatment of ...
Clinical-stage biotech group Puretech Health has announced promising results from the trial of its lung disease treatment ...
PureTech Health (PRTC) announced results from ELEVATE IPF, a Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging ...
Zakir Hussain, the legendary tabla maestro, passed away in San Francisco at the age of 73 on Sunday. He died due to ...
Pirfenidone 267mg, 801mg; film-coated tabs. Take with food at same time each day. Days 1–7: 267mg 3 times daily; Days 8–14: 534mg 3 times daily; Days 15 onward: 801mg 3 times daily.
Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback